uniQure NV (NAS:QURE)
$ 15.3 8.005 (109.73%) Market Cap: 745.77 Mil Enterprise Value: -12.06 Mil PE Ratio: 0 PB Ratio: 13.30 GF Score: 75/100

uniQure N.V. - Special Call Transcript

Dec 08, 2020 / 10:00PM GMT
Release Date Price: $47.51 (+0.53%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to today's top line data from HOPE-B pivotal trial of EtranaDez in hemophilia B. (Operator Instructions) I would also -- I also need to advise you that this conference is recorded today.

Without any further delay, I would now like to hand the conference over to Maria Cantor. Please go ahead.

Maria E. Cantor
uniQure N.V. - Chief Communications Officer

Good afternoon, and thank you for joining us as we review the initial clinical data from the HOPE-B pivotal study of EtranaDez AMT-061 being studied in adult patients with severe and moderately severe hemophilia B. These data were highlighted today in a late-breaker oral presentation featured at the virtual ASH Annual Meeting.

Joining me for this event are Matt Kapusta, our Chief Executive Officer at uniQure; Dr. Ricardo Dolmetsch, our President of Research and Development; Eileen Sawyer, our Vice President of Global Medical Affairs; and Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot